bs-3335R [Primary Antibody]
PKR (Thr446) Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: PKR Thr446

Modification Site: Thr446

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 5610

Swiss Prot: P19525

Source: KLH conjugated synthetic phosphopeptide derived from human PKR around the phosphorylation site of Thr446

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

IFN-induced dsRNA-dependent serine/threonine-protein kinase which plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation. Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1). Inhibits viral replication via phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (EIF2S1), this phosphorylation impairs the recycling of EIF2S1 between successive rounds of initiation leading to inhibition of translation which eventually results in shutdown of cellular and viral protein synthesis. Also phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11. In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteosomal degradation. Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding proinflammatory cytokines and IFNs. Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6. Can act as both a positive and negative regulator of the insulin signaling pathway (ISP). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2).

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 62


Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Hyeon Jin Kim. et al. Structural study of novel vaccinia virus E3L and dsRNA-dependent protein kinase complex. BIOCHEM BIOPH RES CO. 2023 Jul;665:1Read more>>
VALIDATION IMAGES

Mouse brain lysates probed (bs-3335R) at 1:300 overnight in 4˚C. Followed by conjugation to the secondary antibody (bs-0295G-HRP) at 1:5000 90min in RT.


Formalin-fixed and paraffin embedded rat brain tissue labeled with Anti-PKR (Thr446) Polyclonal Antibody, Unconjugated(bs-3335R) 1:200 followed by conjugation to the secondary antibody and DAB staining


Paraformaldehyde-fixed, paraffin embedded human kidney tissue; Antigen retrieval by boiling in sodium citrate buffer(pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37°C for 20min; Antibody incubation with Rabbit Anti-PKR(Thr446) Polyclonal Antibody, Unconjugated (bs-3335R) at 1:500 overnight at 4°C, followed by a conjugated secondary and DAB staining\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t


Lane 1: Human K562 cell lysates; Lane 2: Human A431 cell lysates probed with Phospho-PKR (Thr446) Polyclonal Antibody, Unconjugated (bs-3335R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.